MHRA approves adapted Nuvaxovid JN.1 COVID-19 vaccines for adults and children aged 12 plus

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an adapted version of the Nuvaxovid COVID-19 vaccine that targets the Omicron JN.1 COVID-19 subvariant.